Menu

Snake Venoms Cause and Block Pain

Painful snake bites may hold clues to developing analgesic drugs.

Jan 1, 2018
Kerry Grens

© Matthijs Kuijpers/ALAMY STOCK PHOTO Snakes represent some of the deadliest venomous animals in the world, killing between 81,000 and 138,000 people each year, according to the World Health Organization. But in low doses, some of their toxins can produce analgesia.

For instance, a toxin from the black mamba (Dendroaspis polylepis) inhibits pain by blocking acid-sensing ion channels on the surface of pain-transmitting neurons in mice (Nature, 490:552-55, 2012). Another compound, taken from the venom of the king cobra (Ophiophagus hannah), likewise diminishes pain but acts in an unusual way. R. Manjunatha Kini of the National University of Singapore has found that so-called hannalgesin likely disrupts nitric oxide synthase in neurons, thereby reducing nitric oxide production, which is involved in pain. “There are many ways of skinning a cat, and there could be many ways to block pain,” says Kini.

Although both toxins helped launch companies looking to develop analgesics in recent years, neither progressed, principally because of economic and other circumstances beyond the science, Kini says.

Toxins that cause pain can be just as useful as those which block pain because they can teach us more about how pain works.—Bryan Fry, University of Queensland

The University of Queensland’s Bryan Fry says snake venoms could contribute to pain therapeutics in ways other than by tapping into their analgesic components: by zeroing in on venom compounds that cause pain. In 2016, Fry’s group described the mechanism by which the toxin of the long-glanded blue coral snake (Calliophis bivirgatus) acts upon the NaV1.4 voltage-gated sodium channel (Toxins, 8:303, 2017), “therefore revealing a new target for drug design,” he says in an email to The Scientist. “Toxins that cause pain can be just as useful as those which block pain, because they can teach us more about how pain works.”

Read about other animal groups researchers are exploring for pain-killing leads in the full feature story, “Animal Analgesics.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.